Does Two Make A Trend? 3SBio Joins U.S.-listed Chinese Firms Going Private
This article was originally published in PharmAsia News
Executive Summary
On the heels of ShangPharma, 3SBio’s move highlights depressed valuation for Chinese companies. The large premium should seal the deal for the company with a growing pipeline and revenues, analysts say.
You may also be interested in...
Chinese Pharma Cracking The U.S. Market Via Reverse Mergers Draw Attention From Authorities
HONG KONG - A number of Chinese companies publicly traded in the U.S., including several in the pharmaceutical space, have come under the spotlight in the last 18 months after getting to market through reverse mergers
After Brazil Onto China? Amgen Unveils Emerging Market Strategy
The world's largest biotech company Amgen Inc. aims to triple sales from emerging markets in five years through potential acquisitions and licensing back rights to current products, the company said during an April 21 business review meeting. Amgen's recent purchase of privately held Bergamo of Brazil for roughly $215 million, and its reacquisition of Brazilian rights to certain Amgen products from Mantecorp, indicate more such deals are on the way, analysts say
Amgen Shortens Epogen, Procrit Shelf-lives Following Recall
Firm is working with vial manufacturers to determine the cause of the delamination.